ABOUT IMEXPHARM

Introduction

With a solid foundation - more than 30 years experience in the production, preparation, distribution pharmaceutical, Imexpharm is continuously improving to become a pioneer in the pharmaceutical industry in Vietnam.
front sign Imexpharm

Established since 1977

Formerly known as a Tier II Pharmaceutical Company, overcoming initial difficulties, Imexpharm Pharmaceutical Joint Stock Company has made rapid and stable changes.

Business operations

Imexpharm's main business are manufacturing and trading pharmaceutical products, importing, and purchasing packaging materials for production.

Slogan “Initially Being Committed”

Imexpharm commits to keep promises consistently with our customers to follow the chosen pathway; offer high effective solutions for public health.

EU - GMP

Proud to be the first unit to meet GMP-ASEAN standards and own the most EU-GMP factories in Vietnam.

Becoming a franchised production partner of many leading pharmaceutical corporations in the world such as Sandoz, Robinson Pharma, DP Pharma, Galien, Pharmacience Canada, Sanofi - Aventis. Keep moving, Imexpharm always pays attention to technological improvement and focuses on improving product quality, and human resources to bring quality products and services. Imexpharm owns 3 clusters of factories and has 11 production lines that meet EU-GMP standards. Up to now, Imexpharm is knowns as a pharmaceutical company that owns the most EU-GMP production lines in Vietnam. By the end of 2022, Imexpharm had 12 registration numbers for 7 products in Europe.

Imexpharm EU GMP
Company Name
Imexpharm Corporation
Abbreviated Name
IMEXPHARM
Tax Code
1400384433
Stock Code
IMP
Headquarters
No.4, 30/4 Street, Ward 1, Cao Lanh City, Dong Thap Province
Telephone
0277-3851941
Email
imp@imexpharm.com
Website
www.imexpharm.com

Imexpharm's Structure

Sơ đồ tổ chức IMP English

Partners
Our Vision image

MISSION

Offering effective solutions

for social health care

Cung cấp giải pháp hiệu quả
cao cho sức khỏe cộng đồng

The mission of Imexpharm is to provide high-quality products and healthcare services for everybody.

VISION

Top quality 
European standard

The vision of Imexpharm is to become a leading pharmaceutical firm in the country, with benchmark quality products produced according to European standards (EU-GMP).
Our MIssion image

THE BUSINESS PHILOSOPHY

1000 years later, lotus still in bloom

To confirm a philosophy, determination, and steadfastly following customer service commitments and for the community that Imexpharm has outlined inder the target strategy. Despite all the harsh hardships of life and business, Imexpharm is still confident to succeed in the end, like the longevity, development, and exaltation of the noble lotus. The flower has been transformed into Imexpharm image, brand, and people.

OUR QUALITY POLICY

“Initially being committed” to community health

 

We are committed to:

  1. Ensure our customers receive high-quality products & services in the right quantities and right time as agreements.
  2. Be responsible to physicians and patients who introduce and use our products for quality, safety, and effectiveness.
  3. Facilitate all staff understanding of our quality policy and the best conditions to implement the policy.
  4. Improve the effectiveness of the quality management systems continually, enhance management capability and products & service quality.
  5. Comply with requirements of ISO 9001, GMP, and the laws.

CULTURE

Core Values and The supreme principle

Core Values and The “supreme” principle

  1. Customer focus - Always leading in service
  2. Cooperation - When a problem occurs, consider yourself first
  3. Perseverance - Do not say "no", please give solutions
  4. Enthusiasm - Do not leave until it's done
  5. Learning & Improvement - If you think you're the best, you're being left behind
  6. Efficiency drive - Let's work together by numbers

IMEXPHARM leadership competency

  • Planning, Managing & Implementing of Plans
  • Stewardship of Resources
  • Problem Solving
  • Coaching & Developing Staffs
  • Motivating Staffs
Năng lực lãnh đạo Imexpharm

Journey

Imexpharm's memorable milestones

  • 2022
    The High-tech Factory - IMP4 achieves EU-GMP | SK is deeply involved in governance

    Imexpharm, the domestic pharmaceutical company, owns the most EU-GMP lines in Vietnam

    In September 2022, Binh Duong Hi-tech Factory (IMP4) was officially certified to meet EU-GMP standards, for a total number of 11 EU-GMP production lines to place Imexpharm at the No.1 position in this regard in Vietnam. Also in 2022, a visa to export to European market was granted to 3 additional products, including Cephalexin 250 mg oral suspension, Pantoprazole 40mg lyophilized injection, and Cefixime 200mg film-coated tablets, for a total number of 7 products to enter European market (with 12 registration numbers).
    This was also a turning point in its operations. SK Group (South Korea) undertook to increase its investment in Imexpharm to facilitate its “global reach” journey.
     

  • 2021
    Inauguration of Health Protection Food Factory, European Medicine Visa

    Provide comprehensive health solutions. Proud Vietnamese drug brand international integration.

    In 2021, the Company put into commercial operation its Supplement Factory as part of its head office in Cao Lanh City, Dong Thap province following an investment of VND 82 billion. Also in 2021, Imexpharm successfully registered European Visa for 2 products: Amoxicillin 250 mg oral suspension and Amoxicillin 500 mg capsules, and successfully demonstrated the “bioequivalence” of two products, Zanimex 500mg film-coated tablets and Biocemet DT 500mg/62.5mg dispersible tablets. From this foundation, Imexpharm has firmly made a breakthrough towards exporting high-quality products to fastidious markets.

  • 2020
    Foreign strategic partnership | Partner with Asian Development Bank (ADB)

    In 2020, Imexpharm obtained a European conformity certification for Cefalexin 500 mg capsules. It is important to note that, during this period, Imexpharm’s efforts were backed by international partners and investors. In 2020, SK Group (South Korea) became one of its strategic shareholders and participated in its governance. The Asian Development Bank (ADB) conducted an operational appraisal and provided a loan worth USD 8 million, on a ground of Imexpharm’s transparent, robust, and reliable development.

  • 2019
    IMP4 Inauguration | IMP2 was granted EU-GMP Certification

    IMP4 Hi-tech Factory inaugurated in 2019 with an investment capital of 470 billion VND

    IMP4 Hi-Tech Factory - Binh Duong was inaugurated in 2019 with an investment of 470 billion VND. The factory is considered the golden star of Imexpharm so far. The factory qualified for WHO-GMP in July 2019. Besides, The High-tech antibiotic factory IMP2 - Vinh Loc: September 2018 The Portuguese Ministry of Health approved the factory according to EU-GMP standards. On 02/01/2019 received this certificate.

  • 2018
    IMP2 commenced operation | Groundbreaking ceremony for IMP4
  • 2017
    Vinh Loc High-Tech Antibiotics Plant - IMP 2
  • 2016
    EU-GMP certification | the project of the High-tech Antibiotics Plant in Vinh Loc

    EU-GMP certification Imexpharm became the first domestic pharmaceutical company to obtain simultaneously the EU-GMP certification from the Ministry of Health of Spain (ICH group)

    THE MINISTRY OF HEALTH OF SPAIN GRANTED THE CERTIFICATION OF EU-GMP SIMULTANEOUSLY FOR 03 PRODUCTION LINES OF THE HIGH-TECH BETALACTAM PLANT OF IMEXPHARM IN BINH DUONG The year 2016 became one of the most memorable milestone in the history of development and determination of investing in the core capability of “Product quality” when Imexpharm became the first domestic pharmaceutical company to obtain simultaneously the EU-GMP certification from the Ministry of Health of Spain (ICH group) for 03 production lines in the High-tech Betalactam Plant in Binh Duong being the Cephalosporin tablets and injection production lines and Penicillin injection production lines in September 2016.

    With the advantage of costs of production and being one of the rare domestic enterprises to first obtain EU-GMP, PIC/SGMP certification, Imexpharm expected to develop its market shares well in the middle term and long term on all 3 channels: OTC, ETC and exports, with the target ratio to 2020 of 60%:30%:10% respectively.

    IMPLEMENTATION OF THE PROJECT OF THE HIGH-TECH ANTIBIOTICS PLANT IN VINH LOC On 21 May 2016, the Board of Directors of Imexpharm Corporation approved the implementation of additional investment in the project of the High-tech Antibiotics Plant in Vinh Loc under EU-GMP standard as per Resolution 23/NQHDQT-IMEX, with the projected investment capital being 180 billion VND. The intention regarding the investment in this plant had been planned by the Leadership of Imexpharm several years ago. The high-tech antibiotics plant in Vinh Loc will be soon completed and commissioned by the end of 2018, an investment expected to yield short-term benefits in order to diversify EU-GMP-certified product lines, as well as to ease pressure on the Non-Betalatam Plant in Cao Lanh City which has been overloaded in the face of general pressure on growth.

  • 2015
    Issuance of individual shares to strategic partners

    Construction of Hi-tech factory in Binh Duong according to EU-GMP standards

    Issuing separate stock for strategic partners, like Pha No Pharmaceutical Joint Stock Company to raise the total charter capital to VND 289,426,460,000. Launching construction of the high-tech factory in Binh Duong, following EU-GMP standards, with new products launched onto the market and the expected investment capital of VND 300-350 billion, taken from the owner’s equity.

  • 2014
    Training, repositioning, change of human resources and restructuring of the company according to the BSC

    263,114,860,000 VND was the charter capital in 2014

    The Corporation continued implementing training, rotating staff, human resource changes and company restructuring under BSC. Imexpharm issued shares to increase charter capital to 263,114,860,000 VND from surplus capital and the ESOP employee share program. The company upgraded its Cephalosporin and penicillin factories in Binh Duong to EU-GMP standard; with an estimated budget of 50 billion VND.

  • 2013
    Marking a new improvement in Imexpharm production

    Enzymatic technology for antibiotic products

    The completion and opening of the Corporate Head Office Building, successful deployment of SAP-ERP Project, and deployment of the BSC project for restructuring the company, Re-approval GMPWHO for all factories, and approval WHO-GMP for the Injectable Penicillin factory in Binh Duong. Using materials produced by enzymatic technology of the Spanish DSM Group for well-known antibiotic products, such as pms-CLAMINAT, pms-PHARMOX, pms-OPXIL and pms-IMEDROXIL. Products, which are produced with this technology, are safe for public health and friendly to the environment.

  • 2012
    Imexpharm became the first Pharmaceutical Company to implement full ERP project on all 8 modules

    167,058,100,000 VND was the charter capital in 2012

    Launched SAP-ERP Project. Imexpharm became the first pharmaceutical company to deploy ERP projects across all 8 modules. Completed 10% bonus shares on charter capital, which was increased to 167,058,100,000 VND by drawing from capital surplus.

  • 2011
    To be a partner of Novartis Group - Switzerland

    152,145,000,000 VND charter capital by 2011

    In March - 2011, Novartis Group - Switzerland evaluated Binh Duong Cephalosporin factory to meet the stringent production standards of this partner.

    The Corporation successfully issued shares to increase the charter capital to 152.145 billion VND.

    June - 2011: Started construction of the injectable Penicillin factory at the Vietnam – Singapore II Industrial Park in Binh Duong. This factory applies European technologies and standards to produce powdered and injectable penicillin. The charter capital was increased to 50 billion VND from capital surplus

    July - 2011: Started construction of a new Head Office at Cao Lanh City, Dong Thap. This project provided a completely new look, a physical representation of Imexpharm’s growth in the Mekong Delta Region and nationwide. Capital investment was 28 billion VND.

    December - 2011: Established Binh Tan Sales Branch in Ho Chi Minh City to implement direct distribution of Imexpharm in Ho Chi Minh City area without intermediary distributors.

  • 2010
    Cephalosporin plant in Vietnam - Singapore II Industrial Park at Binh Duong go into operation

    Total investment of 113 billion VND

    Cephalosporin Factory (in Vietnam - Singapore II Industrial Park, Binh Duong Province) officially begins operation in September, with a total investment of 113 billion VND. This factory applies European technologies and standards to produce oral and injectable powder drugs - a new generation of cephalosporin. 2010 also saw the re-evaluation WHO GMP factory system, GSP-WHO warehouse system, and the first year evaluation of GMPWHO for the Binh Duong factory.

  • 2008
    Signed a joint venture contract with Pharma Science - Canada

    130 products have been produced

    Imexpharm signed a joint venture production contract with Pharma Science - Canada. Both parties agreed on the coproduction of 130 products, including 92 with registration codes and 86 marketed products.

  • 2007
    Successfully demonstrated “bioequivalence” antibiotic Imeclor 125 mg

    Charter capital was increased to 116,598,200,000 VND

    Successfully demonstrated “bioequivalence” of Imeclor Antibiotics 125 mg (containing Cefaclor). Charter capital was increased to 116,598,200,000 VND from the payment of dividends and issuing more dividends.

  • 2006
    Quater III/2006: charter capital was increased to 84,000,000,000 VND

    The 1st VN's pharmaceutical company was approved by the State Securities Commission to list shares on the Ho Chi Minh Stock Exchange

    Charter capital was increased to 84 billion VND from issuing 20% bonus shares on charter capital, taken from the investment development fund. Imexpharm was the first pharmaceutical company to get approval from the State Securities Committee to list stock on the Ho Chi Minh City Stock Exchange (HOSE) starting December 4, 2006 under Decision No.76/UBCK

    GPNY using the stock code ‘IMP.’ Invested and upgraded two factories, Betalactam and Non Betalactam, to satisfy GMP-WHO Standard (Good Manufacturing Practices), upgraded the laboratory to satisfy GLP-WHO Standard (Good Laboratory Practices), and upgraded the storage system to satisfy GSP -WHO Standard (Good Storage Practices).

  • 2005
    Charter capital was increased to 64 billion VND

    Awarded a certificate by the National Commission for Economic Cooperation

    Charter capital was increased to 64 billion VND by offering shares to strategic investors.

  • 2001
    The Imexpharm Corporation in 07/2001

    22 billion VND was the charter capital

    Imexpharm became the first equitized pharmaceutical corporation ‘Imexpharm Pharmaceutical JSC’ under Decision No.907/QDTg dated July 25, 2001 with charter capital of 22 billion VND.

  • 1999
    Sending a greeting to European Nations

    The 1st VN's pharmaceutical to produce for international corporations

    Imexpharm looked to Europe in search of a new growth path, which led Imexpharm to become the first pharmaceutical company in Vietnam to perform concession production for large European corporations (Biochemie).

  • 1997
    GMP ASEAN

    The 1st Company produce medicine under ASIAN- GMP standard in Vietnam

    Imexpharm became the first Pharmaceutical Company in Vietnam to meet the Good Manufacturing Practices standard (GMP ASEAN)

  • 1992
    The company was set to be sustainable developing

    150 billion VND in annual revenue

    The Dong Thap People’s Committee established Dong Thap Pharmaceutical Company with Decision No. 120/QDTL. From this day, the company was built in the direction of sustainable development. The latest machinery equipment was installed and the higher qualified staff was recruited for the further development. There were about 200 people in staff and the annual revenue reached over 150 billion VND.

  • 1983
    Imexpharm was founded in September 1983

    30 billion VND - the company annual revenue

    The precursor of Imexpharm, Dong Thap Pharmaceutical United Enterprise, was founded in September, according to Decision no.284/Tccq dated September 28, 1983 by the Dong Thap Department of Health. The staff totaled approximately 70 people, about ten kinds of products being produced manually. The company had annual revenue of about 30 billion VND

  • 1977
    A Tier II Pharmaceutical Company

Achievements

People

Potential

Our Staff

Human resources – the essential factor paid the most attention and investment at Imexpharm.

For Imexpharm, human resources are considered an extremely important factor contributing to the success and sustainable development of the Company. Imexpharm has set out a philosophy of human resource development based on 3 pillars “Excellent expertise - Good Health - Strong Mind”. With this comprehensive development philosophy, Imexpharm is proud to have a team of employees with positive attitudes, profound knowledge, and excellent skills to meet development requirements.
In addition, the salary, bonus, and welfare policies for employees are always amended and supplemented to attract and retain quality employees. 
Among others, much focus has been on training to instill learning motivation for the gradual improvement of technical skills and expertise day by day.
Apart from training and improvement of technical skills, the Company also focuses on developing Imexpharm culture. Rather than external policies, culture, and an iceberg will create an internal motivation to successfully deliver on business and production goals.
On November 9, 2022, Imexpharm received the award of Top 50 Vietnamese attractive employers. This is a prestigious award category in Vietnam, granted by Anphabe with the Vietnam Chamber of Commerce and Industry (VCCI) patronage.

Đội ngũ nhân viên Imexpharm

Finance/Capital

Financial Indicators in 2022 (as at 31 December 2022)

Charter Capital: VND 667 billion

Owner’s Equity: VND 1,894 billion

Total net revenue and other income: VND 1,668 billion

Total assets: VND 2,277 billion

Profit before tax: VND 291.4 billion

IMP - Financial Statement for The Year Ended 31 December 2022

Distribution system

Throughout 45 years of establishment and development, Imexpharm is proud to have built a network of 20 sales branches spreading from North to South. Along with improving team capacity, applying 4.0 into practice, and focusing on improving the model to go deeper, Imexpharm's sales branch network gradually becomes professional, synchronous, and modern. In the near future, the Company plans to open a new branch in the Northern region, in order to gradually realize the goal of increasing the coverage of Imexpharm products, maintaining its commitment from the beginning to bring Vietnamese consumers quality experiences, affirming the leading pharmaceutical manufacturer brand in Vietnam.

BRANCHES, FACTORY DEPARTMENTS

4 Factory clusters including 7 factories and production workshops in Dong Thap, City. Ho Chi Minh and Binh Duong.
20 Sales branches spread across North - Central - South
2 Branch Offices in City. Ho Chi Minh
2 General warehouses in City. Ho Chi Minh and Dong Thap

  • Northern Region

    Ha Noi Branch

    • Address: 26N7A Trung Hoa Newcity – Nhan Chinh Ward, Thanh Xuân. Dist, Ha Noi
    • Phone: 028 7308 7318
    • Email: tamnv@imexpharm.com

    Nghe An Branch

    • Address: Tay New City, Nghi Phu Ward, Vinh City, Nghe An
    • Phone: 0931 099 901
    • Email: trungvt@imexpharm.com
  • Central Region

    Da Nang Branch

    • Address: 423 Nguyen Huu Tho St., Khue Trung Ward, Cam Le Dist., Da Nang
    • Phone: 0914 190 981
    • Email: thoaitc@imexpharm.com

    Binh Dinh Branch

    • Address: B126-B127 Dinh Ruoi St., East Dien Bien Phu Residence, Nhon Binh Ward, Quy Nhon City, Binh Dinh
    • Phone: 0935 679 768
    • Email: vuph@imexpharm.com

    Khanh Hoa Branch

    • Address: 482 Le Hong Phong St., Phuoc Hai Ward, Nha Trang, Khanh Hoa
    • Phone: 0919 199 303
    • Email: nguyendung86@imexpharm.com
  • Ho Chi Minh City

    SALE Branch NO.1

    • Address: C5-4C5, 3A Residence, Ha Huy Giap St., Thanh Loc Ward, Dist.12, Ho Chi Minh City
    • Phone: 0907 112 446
    • Email: tunt@imexpharm.com

    Ho Chi Minh City Branch

    • Address: 63B-65B, Lu Gia Residence, Street No.2, Ward.15, Dist.11, Ho Chi Minh City
    • Phone: 028 38669095 - 028 38669096
    • Email: purchasing@imexpharm.com

    Binh Tan Branch

    • Address: 68-68A Vanh Dai Trong St., Binh Tri Dong Ward, Binh Tan Dist., Ho Chi Minh City
    • Phone: 0906 666 277
    • Email: tinhnv@imexpharm.com
  • Mekong River Delta

    Cuu Long 1 Branch

    • Address: 119 Nguyen Van Voi St., Cai Tau Ha Town, Chau Thanh Dist., Dong Thap
    • Phone: 0915 725 152
    • Email: liemnt@imexpharm.com

    Cuu Long 2 Branch

    • Address: 66A Nguyen Tat Thanh St., Ward 1, Sa Dec City, Dong Thap
    • Phone: 0908 732 718
    • Email: sybt@imexpharm.com

    An Giang Branch

    • Address: 16-18 Hung Vuong St., My Phuoc Ward, Long Xuyen City, An Giang
    • Phone: 0918 489 916
    • Email: nganpq@imexpharm.com

    Cuu Long 4 Branch

    • Address: No 3 - 4, Block C4, 11D Residence, Phu Thu Ward, Cai Rang Dist., Can Tho City
    • Phone: 0913 368 713
    • Email: chanhhc@imexpharm.com

    Cuu Long 5 Branch

    • Address: 69 Pham Ngoc Thach St., Ward 5, Ca Mau City
    • Phone: 0977 222 922
    • Email: congnt@imexpharm.com

    Kien Giang Branch

    • Address: 337 Mac Cuu Street, Vinh Thanh Ward, Rach Gia City, Kien Giang
    • Phone: 0915 725 152
    • Email: liemnt@imexpharm.com

    Dong Thap Branch

    • Address: No.04, 30/4 Street, Ward 1, Cao Lanh City, Dong Thap
    • Phone: 0913 965 699
    • Email: thont@imexpharm.com

    Tien Giang Branch

    • Address: 22 Hung Vuong Street, Dao Thanh Ward, My Tho City, Tien Giang
    • Phone: 0908 732 718
    • Email: sybt@imexpharm.com
  • Southeastern Region

    Tay Nguyen Branch

    • Address: 28 Dang Thai Mai Street, Tan Loi Ward, Buon Ma Thuoc City, Dak Lak
    • Phone: 0908 061 661
    • Email: vandt@imexpharm.com

    Dong Nai Branch

    • Address: K44 Quarter No.1, Buu Long Ward, Bien Hoa City, Dong Nai
    • Phone: 0938 884 652
    • Email: hients@imexpharm.com

    Binh Duong Branch

    • Address: 1362 My Phuoc Tan Van St., Phu My Ward, Thu Dau Mot City, Binh Duong
    • Phone: 0937 366 839
    • Email: binhnt@imexpharm.com

    Tay Ninh Branch

    • Address: 131 Quarter No.3, Nguyen Thai Hoc St., Ward 3, Tay Ninh City, Tay Ninh
    • Phone: 0918 626 678
    • Email: thonh@imexpharm.com

    Ba Ria - Vung Tau Branch

    • Address: 41-43 , Nguyen Khanh Toan St., Phuoc Nguyen Ward, Ba Ria City, Ba Ria Vung Tau
    • Phone: 0909 752 266
    • Email: quyenlm@imexpharm.com

International Representation

With quality standards built up, Imexpharm believes that the journey of "Global Integration", penetrating into extreme markets and competing directly with international businesses is inevitable. The term 2023-2027 will be the period when Imexpharm expands the market and promotes the export of products, especially for those that already have a European Visa.

Factory system

Dong Thap - IMP 1

Image IMP1 2023

Imexpharm Factory – Dong Thap

  • Address: No 04, 30/4 Street, Ward 1, Cao Lanh City, Dong Thap Province
  • Phone: (0277) 3851941

Non-Betalactam Plant

Manufacturing tablet or medicine packet.

The first pharmaceutical plant in Vietnam to be granted ASEAN-GMP certification in 1997.

In 2006, was upgraded to become the first plant in Vietnam to meet WHO-GMP standards.

1.200 million units a year.

Nhà máy IMP3 Cefalosporin

Penicillin plant

Manufacturing tablet or medicine packet.

Was ASEAN-GMP certified in 1998.

In 2006, it was upgraded along with the Non plant and became one of the earliest plants to receive WHO-GMP certification.

300 million tablets a year.

Tp. HCM - IMP 2

D-U-N-S Number: 557049273
Imexpharm IMP 2 EU GMP Standard

Vinh Loc High-Tech Antibiotics Plant

  • Address: B16/1, 2A Street, Vinh Loc Industrial Zone, Binh Tan District, Ho Chi Minh City
  • Phone: 0283 765 2536
  • Fax: 0283 765 2537

The plant is reviewed for EU-GMP standards and anticipates to be completed and commissioned by the end of 2018, then it will go into operation in early 2019. The designed capacity is 250 million units a year. The total capital investment is 180 billion VND.

The factory was granted EU-GMP certification by the Portuguese Ministry of Health on January 2, 2019.

IMP2 EU-GMP Standard

Form of products manufactured by the factory:

Hard capsules, Tablets, Film-coated tablets, Packaged products

Imexpharm-IMP-2-EU-GMP-Standard-1
Imexpharm-IMP-2-EU-GMP-Standar-2

IMP-2 EU-GMP Standard

Product group: Penicillin

Product Quality: Pharmacopoeia EP, USP, BP

Binh Duong - IMP 3

D-U-N-S Number: 556506891
IMP3 Cefalosporin Factory

Branch No. 3 – Binh Duong

  • No.22, Street No. 2, VSIP II Industrial Zone, Hoa Phu Ward, Thu Dau Mot City, Binh Duong Province.
  • Phone: 0274 3815 166
  • Fax: 0274 3815 169

The Plant includes 2 separate manufacturing buildings: The Penicillin Plant and Cephalosporin Plant are totally separated from different buildings, HVAC systems, warehouses, QC laboratory, and other utilities.

Cephalosporin building

First was built applying European technologies and standards to produce a new generation of Cephalosporin with an estimated budget of 113 billion VND. WHO-GMP certified in 2010.

Was upgraded to EU-GMP standards in 2014.

Was granted an EU-GMP certification by the Health Ministry of Spain in 9/2016. The Health Ministry of Vietnam announced that in 11/2016.

Producing injectable powder and tablet products, 12 million bottles and 500 million units a year.

Product range:

  • Sterile: Powder for injection
  • Non-sterile: Hard capsule, Film-coated tablet, Sachet
Nhà máy IMP3 Cefalosporin
Nhà máy Penicillin

Penicillin Manufacturing Plant

Was built using European technologies, and received WHO-GMP certification in 2013 with an investment budget of 50 billion VND. In 2014, it continued to be upgraded to EU-GMP standards.

Was given an EU-GMP certification by the Spanish Ministry of Health, Social Services, and Equality in 9/2016. The Health Ministry of Vietnam announced that in 11/2016.

Manufacturing powdered and injectable penicillin, 10 million bottles a year.

Product range:

  • Sterile: Powder for injection

Binh Duong - IMP 4

D-U-N-S Number: 5566697400
Imexpharm Hi-tech Pharmaceutical Plan 1

Binh Duong High-tech Pharmaceutical Plant

Was built to EU-GMP standards, producing specialty drugs with some special dosage forms.

  • The total invested capital was 470 billion VND.
  • Scheduled to finish by the end of 2019, go into operation at the beginning of 2020, and reached EU-GMP standards in early 2022.

This is the factory with the highest scale of technology and investment fund of Imexpharm. IMP4 carries with it the most advanced technologies of the pharmaceutical industry in Vietnam such as the line of lyophilized powder for injection for both Steroid and Non-Steroid drug groups and the Blow Fill Seal (BFS) injection line. Average total capacity 23,940,000 units/year

Blow Fill Seal (BFS)

BFS production line is invested in a modern and methodical manner with equipment imported directly from Europe.

Inside BFS IMP4 Binh Duong
Inside IMP4 Binh Duong

Binh Duong High-tech Pharmaceutical Plant

By 2022, Imexpharm owns 02 lines of lyophilized powder for injection.

Confirmation

1. If you are a health worker:

These are only summaries of the instructions. Please see medication guides for complete information.

2. If you are a user:

Please contact your doctors or pharmacists for medication directions.

Back to Main page Confirm